Suppr超能文献

基于粪便的微小RNA谱用于早期结直肠癌筛查的初步评估。

A preliminary assessment of a stool-based microRNA profile for early colorectal cancer screening.

作者信息

Santos Daniela A R, Eiras Mariana, Gonzalez-Santos Miguel, Santos Marlene, Pereira Carina, Santos Lúcio Lara, Dinis-Ribeiro Mário, Lima Luís

机构信息

Experimental Pathology and Therapeutics Group, Research Centre of IPO Porto (CI- IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (Porto.CCC), Porto, 4200-072, Portugal.

Faculty of Medicine of the University of Porto (FMUP), Porto, 4200-319, Portugal.

出版信息

Sci Rep. 2025 Aug 5;15(1):28597. doi: 10.1038/s41598-025-14485-z.

Abstract

Colorectal cancer screening methods are well established worldwide as a fundamental pilar in CRC management, namely through non-invasive faecal occult blood testing. However, the limited sensitivity of faecal occult blood test for detecting precancerous lesions highlights the need to search for alternative tools, such as microRNAs (miRs). The main aim of this study was to identify stool-based miR profiles for early colorectal cancer detection. A panel with miR-21-5p, miR-199a-5p, and age showed a moderate performance for colorectal cancer detection (sensitivity: 88%). Additionally, miR-451a, miR-21-5p, miR-199a-5p, age, and gender showed high performance for discriminating high-grade dysplasia lesions (sensitivity: 91%). Moreover, when we obtained a positive result in either panel, we achieved a sensitivity of 96% for high-grade dysplasia lesions identification. Finally, when a negative result was obtained in these panels after a positive faecal occult blood test result, we accurately identified individuals without lesions. These findings demonstrate the potential of miR panels as non-invasive biomarkers for colorectal cancer and high-grade dysplasia lesions detection and could constitute a secondary screening method following a positive faecal occult blood test.

摘要

在全球范围内,结直肠癌筛查方法已被确立为结直肠癌管理的一项基本支柱,具体是通过非侵入性的粪便潜血检测。然而,粪便潜血检测在检测癌前病变方面的敏感性有限,这凸显了寻找替代工具的必要性,比如微小RNA(miR)。本研究的主要目的是确定基于粪便的miR谱以用于早期结直肠癌检测。一个包含miR-21-5p、miR-199a-5p和年龄的检测组在结直肠癌检测方面表现中等(敏感性:88%)。此外,miR-451a、miR-21-5p、miR-199a-5p、年龄和性别在鉴别高级别发育异常病变方面表现出色(敏感性:91%)。而且,当我们在任一检测组中获得阳性结果时,在识别高级别发育异常病变方面的敏感性达到了96%。最后,当在粪便潜血检测结果为阳性后这些检测组得到阴性结果时,我们准确地识别出了无病变个体。这些发现证明了miR检测组作为结直肠癌和高级别发育异常病变检测的非侵入性生物标志物的潜力,并且可以构成粪便潜血检测结果为阳性后的一种二次筛查方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验